M. Nangaku

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
M Nangaku, Masaomi Nangaku
Publication record
191 papers · 1,548 citations · H-index 11

PAPERS

Design of the Japan Kidney Association-Pemafibrate Intervention for Chronic Kidney Disease patients Study (JKAPI-CKD study)
20260 citationsauthor #4
Association between early proteinuria reduction and kidney outcomes in Japanese patients with IgA nephropathy: The Japan Chronic Kidney Disease Database
20260 citationsauthor #5
Population attributable fraction of modifiable risk factors for incident hypertension: an analysis of large-scale epidemiological cohort.
20260 citationsauthor #17
Ventricular fibrillation triggered by recurrent hypoglycemia in a patient with insulinoma associated with MEN1: case report and review of literature.
20260 citationsauthor #13
Real-world use of HIF-PH inhibitors in the Japan dialysis and practice patterns study (J-DOPPS, 2019-2022).
20260 citationsauthor #7
SGLT2 Inhibitor‐Associated Changes in Urinary Volatile Organic Compounds in Diabetic Kidney Disease: A Comprehensive Study
20260 citationsauthor #7
SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study.
20260 citationsauthor #14
Predicted Lean Body Mass and the Risk of Adverse Kidney Outcomes in Men.
20260 citationsauthor #14
In response to lean body mass index and hypertension risk in men: a nationwide epidemiological cohort study.
20260 citationsauthor #10
Efficacy of a Personalized Mobile Health Intervention (BedTime) to Increase Sleep Duration Among Short-Sleeping Patients With Type 2 Diabetes: Protocol for a Pilot Randomized Controlled Trial
20250 citationsauthor #20
589-P: Using One-Shot Prompting of Fine-Tuned Commercial Artificial Intelligence Models to Assess Nutrients from Photographs of Japanese Meals
20251 citationsauthor #5
Detection of Fast Decliner of Diabetic Kidney Disease Using Chiral Amino Acid Profiling: A Pilot Study
20253 citationsauthor #7
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
20252 citationsauthor #41
Hyponatremia after pediatric surgery: Randomized trial of fluid composition on antidiuretic hormone response
20250 citationsauthor #4
Correction: Glycemic Control, Renal Progression, and Use of Telemedicine Phone Consultations Among Japanese Patients With Type 2 Diabetes Mellitus During the COVID-19 Pandemic: Retrospective Cohort Study
20250 citationsauthor #7
Artificial-Intelligence-Based Trajectory Clustering Analysis Identifies High-Risk and Previously Overlooked Patients with CKD
20250 citationsauthor #7
Coronavirus Disease 2019 Vaccination Booster Effectiveness Based on the 2022 Japanese Dialysis Registry
20250 citationsauthor #5
Lean body mass index and hypertension risk in men: a nationwide epidemiological cohort study.
20252 citationsauthor #10
Adherence to physician visits for diabetes care and cardiovascular disease risk: A retrospective cohort study using an administrative claims database
20250 citationsauthor #7
OR23-05 Acquired Osteomalacia Associated with Autoantibodies against PHEX
20250 citationsauthor #8
Cardiovascular-kidney-metabolic syndrome stage predicts cardiovascular outcomes in cancer patients: a real-world data analysis of a nationwide epidemiological dataset
20250 citationsauthor #15
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
202591 citationsauthor #15
Maintaining kidney health in aging societies: a JSN and ERA call to action
202510 citationsauthor #4
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
20251 citationsauthor #8
Impact of the COVID-19 Pandemic on Health Check-ups before and after the COVID-19 Downgrade and Employees’ Mental Health at Health Check-up Facilities: The Third Nationwide Survey of Healthcare Facilities in Japan Society of Ningen Dock and Preventive Medical Care
20250 citationsauthor #9
PHEX protein in the parathyroid gland contributes to phosphate sensing.
20251 citationsauthor #8
Attenuation of Proximal Tubule Injury and Kidney Fibrosis with Canagliflozin in a Nonalbuminuric Calcineurin Inhibitor Nephrotoxicity Mouse Model
20250 citationsauthor #2
Metabolomics Uncover a Lipid-Driven Signature of Albuminuria-Independent CKD
20250 citationsauthor #8
Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study
20251 citationsauthor #12
Implementation of Established Global Guidelines in the Management of CKD in Patients with Type 2 Diabetes in Asia.
20251 citationsauthor #2
Validation of Sleep Measurements of an Actigraphy Watch: Instrument Validation Study
20251 citationsauthor #7
Sodium Polystyrene Sulfonate and Heart Failure Risk: A Comparative Study With Calcium Polystyrene Sulfonate
20250 citationsauthor #13
Relative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference
20250 citationsauthor #10
Using One-Shot Prompting of Non-Fine-Tuned Commercial Artificial Intelligence to Assess Nutrients from Photographs of Japanese Meals.
20251 citationsauthor #4
Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New‐User Active Comparator Cohort Study
20251 citationsauthor #6
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics
202511 citationsauthor #15
Children Comorbidity Score, a Simple Predictor for In-hospital Mortality: A Nationwide Inpatient Database Study in Japan
20250 citationsauthor #10
Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.
20250 citationsauthor #22
Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)
20256 citationsauthor #7
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study
20251 citationsauthor #15
Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.
20251 citationsauthor #6
631-P: Increasing Sleep Duration among Short-Sleeping Type 2 Diabetes Patients via mHealth—A Pilot Randomized Controlled Trial
20251 citationsauthor #20
The organelle tethering protein PDZD8 regulates endolysosomal maturation and TLR9-NF-κB signaling in cisplatin-induced acute kidney injury.
20250 citationsauthor #11
Dietary Fiber Estimate of DialBetesPlus App Users: Secondary Analysis of Data From a Randomized Controlled Trial
20251 citationsauthor #5
Effect of SGLT2i on kidney outcomes of individuals with type2 diabetes according to blood pressure levels.
20250 citationsauthor #15
WCN25-2085 COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN FOR CHRONIC KIDNEY DISEASE BASED ON eGFR- AND ALBUMINURIA-BASED SUBGROUPS
20250 citationsauthor #5
Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment
20253 citationsauthor #7
Pyruvate Dehydrogenase and Cellular Metabolism in Calcineurin Inhibitor-Induced Kidney Fibrosis.
20250 citationsauthor #7
The increasing burden of mild and moderate anaemia in CKD
20250 citationsauthor #2
Adherence to monitoring iron indices at the initiation of erythropoiesis-stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitors
20250 citationsauthor #4
Pharmacological prolyl hydroxylase inhibition enhances high‐intensity exercise capacity in mice
20252 citationsauthor #11
Impact of the COVID-19 pandemic and COVID-19 downgrade on non-COVID-19 respiratory diseases in Japan.
20250 citationsauthor #8
Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database
20252 citationsauthor #12
A Comprehensive Skin Gas Analysis of Substances Related to Uraemia in Patients With End‐Stage Kidney Disease: A Pilot Study
20250 citationsauthor #8
Skin perfusion pressure in lower extremities at haemodialysis initiation is associated with 1-year mortality and cardiovascular disease
20250 citationsauthor #7
689-P: What Predicts Intention to Increase Dietary Fiber Intake among Patients with Type 2 Diabetes? A Survey Based on the Theory of Planned Behavior (TPB)
20251 citationsauthor #11
Fibrillary Glomerulonephritis and Multiple Myeloma: A Case Report and Literature Review
20250 citationsauthor #9
Attribute based cross classification analyses from the BRIGHTEN study reveal that therapeutic responsiveness to erythropoiesis stimulating agents predicts cardiorenal prognosis in renal anemia
20251 citationsauthor #3
Relationship between medication use and non‐attendance (missed appointment) from primary care visits among people with type 2 diabetes: The Japan Diabetes Outcome Intervention Trial‐2 Large‐Scale Trial 006 (J‐DOIT2‐LT006)
20251 citationsauthor #8
Real-World Safety and Effectiveness of Vadadustat in Patients with Chronic Kidney Disease-Related Anemia: Interim Analysis of Postmarketing Surveillance in Japan
20252 citationsauthor #1
Temporal trends in time toxicity of R-CHOP: a nationwide hospital-based database analysis in Japan
20251 citationsauthor #5
Digital Therapeutics and Type 2 Diabetes: A Review
20250 citationsauthor #4
Pathogenic variants prevalence patients with diabetic kidney disease in Japan: A descriptive study
20251 citationsauthor #6
Guatemala's resolution on kidney health: a historic opportunity.
20252 citationsauthor #2
Epigenetic memories induced by hypoxia in AKI-to-CKD transition
20251 citationsauthor #2
Preoperative rehabilitation and in-hospital mortality in delayed hip fracture surgery: a nationwide cohort study with stratification by kidney function
20250 citationsauthor #9
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
20252 citationsauthor #17
ASXL1 in Proinflammatory Macrophages Has a Protective Role in AKI by Inhibiting Inflammatory Response
20250 citationsauthor #2
COVID-19 vaccination hesitancy among hemodialysis patients: A mixed-methods study
20250 citationsauthor #9
Sex differences in the progression of cardiovascular–kidney–metabolic syndrome
20250 citationsauthor #16
Clinically meaningful eGFR slope as a surrogate endpoint differs across CKD stages and slope evaluation periods: the CKD-JAC study
20257 citationsauthor #4
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
20251 citationsauthor #7
Inhibition of Hypoxia-Inducible Factor-Prolyl Hydroxylase in Proximal Tubules Lowers Systemic Blood Pressure by Upregulating the Renal Expression of Adrenomedullin
20250 citationsauthor #8
Increasing Prescription of SGLT2 Inhibitors with Expanded Indications to the Elderly Population in Japan
20251 citationsauthor #5
Global availability of medications and health technologies for kidney care: A multinational study from the ISN-GKHA
20252 citationsauthor #10
Changing paradigms of studies in kidney diseases.
20250 citationsauthor #15
Association between Rheumatoid Arthritis and the Incidence of IgA Nephropathy
20251 citationsauthor #14
Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)
20250 citationsauthor #28
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis
20250 citationsauthor #3
1863-LB: The Confidence Trial—Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes
20250 citationsauthor #14
Personalized mHealth Intervention (StepAdd) for Increasing Physical Activity in Japanese Patients With Type 2 Diabetes: Secondary Analysis of Social Cognitive Theory Measurements of a Single-Arm Pilot Study
20253 citationsauthor #4
Metrics for Evaluating Telemedicine in Randomized Controlled Trials: Scoping Review
20253 citationsauthor #6
Efficacy of FiberMore, an AI-Based mHealth Intervention to Increase Dietary Fiber Intake Among Type 2 Diabetes Patients: Protocol for a Pilot Randomized Controlled Trial
20250 citationsauthor #21
Blood hemoglobin levels of the general population residing at low range altitudes
20241 citationsauthor #5
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
202414 citationsauthor #33
Factors affecting the sodium‐glucose cotransporter 2 inhibitors‐related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database
20244 citationsauthor #6
Erythropoiesis‐stimulating agent hyporesponsiveness was associated with worse survival of hemodialysis patients independent of the serum ferritin level
20240 citationsauthor #8
Landscape of kidney replacement therapy provision in low- and lower-middle income countries: A multinational study from the ISN-GKHA
20249 citationsauthor #11
Issues in the Adoption of Online Medical Care: Cross-Sectional Questionnaire Survey
20245 citationsauthor #11
Structures for quality assurance and measurements for kidney replacement therapies: A multinational study from the ISN‐GKHA
20241 citationsauthor #12
Global structures, practices, and tools for provision of chronic peritoneal dialysis.
20248 citationsauthor #11
Disparities in kidney care in vulnerable populations: A multinational study from the ISN-GKHA
20243 citationsauthor #14
'DKD' as the kidney disease relevant to individuals with diabetes
20245 citationsauthor #2
“Call for Action” for the challenges of kidney diseases in aging/aged societies
20240 citationsauthor #1
Global Policy and Advocacy Initiatives for Improving Kidney Care
20242 citationsauthor #10
[Clinical application and future perspectives of HIF-PH inhibitors].
20240 citationsauthor #1
A Case of Post-transplant Lymphoproliferative Disorder Developed 45 Years after Kidney Transplantation
20240 citationsauthor #4
A global assessment of kidney care workforce.
202410 citationsauthor #14
Ablation of Type 2 IP3R, a Calcium Channel Located on the Organelle Contact Site, Improves the Repairment of Cell Survival and Endoplasmic Reticulum-Mitochondria Function in Tubular Cells
20240 citationsauthor #4
Global data monitoring systems and early identification for kidney diseases.
20242 citationsauthor #11

TIMELINE

2010 9 citations

2017 62 citations

2020 0 citations

2021 0 citations

2022 0 citations

2023 119 citations

2024 1,219 citations

2025 174 citations

2026 0 citations

Unknown 0 citations

M. Nangaku

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT